BioSpace News Archive

City of Hope and Osel, Inc. today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of a LBP CBM588 to enhance efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.

Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announced today that the first participant has been successfully dosed in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain.

It’s hard to imagine losing your ability to have children when you’re only 30-years-old. But for women who suffer from uterine fibroids, that could be the reality if their doctor recommends they undergo a hysterectomy.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that it has filed a 510 submission with the FDA for an expansion of capabilities on the previously cleared Intelligent Surgical Unit™.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it has signed a lease agreement for a facility to support research and development and future commercial manufacturing of Nkarta’s cell therapy pipeline.

Surgical care continues to be under threat in the proposed Medicare Physician Fee Schedule for calendar year 2022 released yesterday by the Centers for Medicare & Medicaid Services.

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 fourth-quarter conference call on Wednesday, August 4, 2021, at 3:30 p.m. CT (4:30 p.m. ET).

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the closing of a multi-year licensing agreement with University Hospitals Dorset NHS Foundation Trust (the “Trust” or “Dorset”) in support of the initial deployment of the novel NHS “Thing Big” initiative.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2021.